Indian Journal of Critical Care Medicine

Register      Login



Volume / Issue

Online First

Related articles

VOLUME 25 , ISSUE 12 ( December, 2021 ) > List of Articles

Original Article

Disseminated Intravascular Coagulation Score and Sepsis-induced Coagulopathy Score in Prediction of COVID-19 Severity: A Retrospective Analysis

Mayank Kapoor, Prasan Kumar Panda, Lokesh Kumar Saini, Yogesh Bahurupi

Keywords : Coronavirus disease-2019, Disseminated intravascular coagulation score, Hospital mortality, Pulmonary embolism, Sepsis-induced coagulopathy score

Citation Information : Kapoor M, Panda PK, Saini LK, Bahurupi Y. Disseminated Intravascular Coagulation Score and Sepsis-induced Coagulopathy Score in Prediction of COVID-19 Severity: A Retrospective Analysis. Indian J Crit Care Med 2021; 25 (12):1357-1363.

DOI: 10.5005/jp-journals-10071-24056

License: CC BY-NC 4.0

Published Online: 17-12-2021

Copyright Statement:  Copyright © 2021; The Author(s).


Background: The novel disseminated intravascular coagulation (DIC) score (platelet count, prolonged prothrombin time, D-dimer, and fibrinogen) and sepsis-induced coagulopathy (SIC) score (platelet count, international normalized ratio, and sequential organ failure assessment score) are markers of coagulopathy, which, for the first time, are explored in line with the coronavirus disease-2019 (COVID-19) disease outcomes. The correlation of D-dimer with these findings is also studied. Materials and methods: A retrospective analysis of hospital-based records of 168 COVID-19 patients was done. Data including D-dimer, routine investigations, DIC, and SIC scorings (all within 3 days of admission) were collected and correlated with the outcomes. The study was conducted in a tertiary care center catering to North India's population. Results: Higher DIC score (1.59 ± 1.18 vs 0.96 ± 1.18), SIC score (1.60 ± 0.89 vs 0.63 ± 0.99), and D-dimer titers (1321.33 ± 1627.89 vs 583·66 ± 777.71 ng/mL) were significantly associated with severe COVID-19 disease (p <0.05). DIC score and SIC score ≥1, and D-dimer ≥1315 ng/mL for severe disease; DIC score ≥1, SIC score ≥2, and D-dimer ≥600 ng/mL for pulmonary embolism (PE); and DIC score and SIC score ≥1, and D-dimer level ≥990 ng/mL for mortality were the respective cutoff values we found from our study. Conclusion: Higher DIC scores, SIC scores, and D-dimer values are associated with severe COVID-19 disease, inhospital mortality, and PE risk. They can serve as easily accessible early markers of severe disease and prioritize hospital admissions in the presently overburdened scenario and may be used to develop prognostic prediction models.

  1. Chandrashekar V. DIC score: statistical relationship with PT, APTT, and simplified scoring systems with combinations of PT and APTT. ISRN Hematol 2012;2012:1–4. DOI: 10.5402/2012/579420.
  2. Taylor F, Toh C-H, Hoots K, Wada H, Levi M. Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost 2001;86(11):1327–1330. DOI: 10.1055/s-0037-1616068. Available from:
  3. Iba T, Di Nisio M, Levy JH, Kitamura N, Thachil J. New criteria for sepsis induced coagulopathy (SIC) following the revised sepsis definition: a retrospective analysis of a nationwide survey. BMJ Open 2017;7(9). DOI: 10.1136/bmjopen-2017-017046. Available from: /pmc/articles/PMC5623518/?report=abstract.
  4. Singer M, Deutschman CS, Seymour C, Shankar-Hari M, Annane D, Bauer M, et al. The third international consensus definitions for sepsis and septic shock (sepsis-3) JAMA 2016;315(8):801–810. DOI: 10.1001/jama.2016.0287. Available from: /pmc/articles/PMC4968574/.
  5. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395(10223):497–506. DOI: 10.1016/S0140-6736(20)30183-5. Available from:
  6. Why COVID-19 makes some people sicker than others. The Atlantic 2020. Available from:
  7. Velavan TP, Meyer CG. Mild versus severe COVID-19: laboratory markers. Int J Infect Dis 2020;95:304–307. DOI: 10.1016/j.ijid.2020.04.061.
  8. Michel L, Rassaf T, Totzeck M. Biomarkers for the detection of apparent and subclinical cancer therapy-related cardiotoxicity. J Thorac Dis 2018;10(Suppl. 35):S4282–S4295. DOI: 10.21037/jtd.2018.08.15. Available from:
  9. Ryu SH, Min SW, Kim JH, Jeong HJ, Kim GC, Kim DK, et al. Diagnostic significance of fibrin degradation products and d-dimer in patients with breast cancer-related lymphedema. Ann Rehabil Med 2019;43(1):81–86. DOI: 10.5535/arm.2019.43.1.81. Available from:
  10. Payus AO, Rajah R, Febriany DC, Mustafa N. Pulmonary embolism masquerading as severe pneumonia: a case report. Open Access Maced J Med Sci 2019;7(3):396–399. DOI: 10.3889/oamjms.2019.114. Available from:
  11. Tasić N, Paixão TRLC, Gonçalves LM. Biosensing of D-dimer, making the transition from the central hospital laboratory to bedside determination. Talanta 2020;207:120270. DOI: 10.1016/j.talanta.2019.120270.
  12. Favresse J, Lippi G, Roy PM, Chatelain B, Jacqmin H, ten Cate H, et al. D-dimer: preanalytical, analytical, postanalytical variables, and clinical applications. Crit Rev Clin Lab Sci 2018;55(8):548–577. DOI: 10.1080/10408363.2018.1529734. Available from:
  13. Boonyawat K, Chantrathammachart P, Numthavej P, Nanthatanti N, Phusanti S, Phuphuakrat A, et al. Incidence of thromboembolism in patients with COVID-19: a systematic review and meta-analysis. Thromb J 2020;18(1):34. DOI: 10.1186/s12959-020-00248-5. Available from:
  14. Available from: ClinicalManagementProtocolforCOVID19dated03072020.pdf.
  15. England imposes new national lockdown to combat COVID-19 resurgence. Reuters 2020. Available from:
  16. Kapoor M, Dhar M. A look into possible new treatment modality for COVID-19: ACE 2. 2020. Available from:
  17. Pedersen SF, Ho YC. SARS-CoV-2: a storm is raging. J Clin Invest 2020;130(5):2202–2205. DOI: 10.1172/JCI137647. Available from:
  18. Guo H, Sheng Y, Li W, Li F, Xie Z, Li J, et al. Coagulopathy as a prodrome of cytokine storm in COVID-19-infected patients. Front Med 2020;7:572989. DOI: 10.3389/fmed.2020.572989. Available from: /pmc/articles/PMC7645068/.
  19. Lillicrap D. Disseminated intravascular coagulation in patients with 2019-nCoV pneumonia. J Thrombosis Haemost 2020;18(4):786–787. DOI: 10.1111/jth.14781. Available from: https://pubmed.ncbi.nlm.
  20. Venous thromboembolism. NHLBI. NIH. Available from:
  21. Paliogiannis P, Mangoni AA, Dettori P, Nasrallah GK, Pintus G, Zinellu A. D-Dimer concentrations and COVID-19 severity: a systematic review and meta-analysis. Front Public Health 2020;8:1–7. DOI: 10.3389/fpubh.2020.00432. Available from:
  22. Yu HH, Qin C, Chen M, Wang W, Tian DS. D-dimer level is associated with the severity of COVID-19. Thromb Res 2020;195:219–225. DOI: 10.1016/j.thromres.2020.07.047. Available from: /pmc/articles/PMC7384402/?report=abstract.
  23. Ozen M, Yilmaz A, Cakmak V, Beyoglu R, Oskay A, Seyit M, et al. D-Dimer as a potential biomarker for disease severity in COVID-19. Am J Emerg Med 2021;40:55–59. DOI: 10.1016/j.ajem.2020.12.023.
  24. Gungor B, Atici A, Baycan OF, Alici G, Ozturk F, Tugrul S, et al. Elevated D-dimer levels on admission are associated with severity and increased risk of mortality in COVID-19: a systematic review and meta-analysis. Am J Emerg Med 2021;39:173–179. DOI: 10.1016/j.ajem.2020.09.018.
  25. Li XY, Du B, Wang YS, Kang HYJ, Wang F, Sun B, et al. [The keypoints in treatment of the critical coronavirus disease 2019 patient]. Zhonghua Jie He He Hu Xi Za Zhi 2020;43(0):E026. DOI: 10.3760/cma.j.cn112147-20200224-00159. Available from:
  26. Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost 2020;18(5):1094–1099. DOI: 10.1111/jth.14817. Available from:
  27. Yao Y, Cao J, Wang Q, Shi Q, Liu K, Luo Z, et al. D-dimer as a biomarker for disease severity and mortality in COVID-19 patients: a case control study. J Intensive Care 2020;8(1):49. DOI: 10.1186/s40560-020-00466-z. Available from:
  28. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020;395(10229): 1054–1062. DOI: 10.1016/S0140-6736(20)30566-3.
  29. Soni M, Gopalakrishnan R, Vaishya R, Prabu P. D-dimer level is a useful predictor for mortality in patients with COVID-19: analysis of 483 cases. Diabetes Metab Syndr Clin Res Rev 2020;14(6):2245–2249. DOI: 10.1016/j.dsx.2020.11.007. Available from: /pmc/articles/PMC7670909/?report=abstract.
  30. Kho J, Ioannou A, Van den Abbeele K, Mandal AKJ, Missouris CG. Pulmonary embolism in COVID-19: alinical characteristics and cardiac implications. Am J Emerg Med 2020;38(10):2142–2146. DOI: 10.1016/j.ajem.2020.07.054. Available from: /pmc/articles/PMC7378013/?report=abstract.
  31. Ventura-Díaz S, Quintana-Pérez JV, Gil-Boronat A, Herrero-Huertas M, Gorospe-Sarasúa L, Montilla J, et al. A higher D-dimer threshold for predicting pulmonary embolism in patients with COVID-19: a retrospective study. Emerg Radiol 2020;27(6):679–689. DOI: 10.1007/s10140-020-01859-1.
  32. Wu Y, Xiao YX, Huang TY, Zhang XY, Zhou HB, Zhang XX, et al. What makes D-dimer assays suspicious–heterophilic antibodies? J Clin Lab Anal 2019;33(2):22687. DOI: 10.1002/jcla.22687. Available from:
  33. Zhang D, Li F, Du X, Zhang X, Zhang Z, Zhao W, et al. Diagnostic accuracy of biomarker D-dimer in patients after stroke suspected from venous thromboembolism: a diagnostic meta-analysis. Clin Biochem 2019;63:126–134. DOI: 10.1016/j.clinbiochem. 2018.09.011. Available from:
  34. Terpos E, Ntanasis-Stathopoulos I, Elalamy I, Kastritis E, Sergentanis TN, Politou M, et al. Hematological findings and complications of COVID-19. Am J Hematol 2020;95(7):834–847. DOI: 10.1002/ajh.25829. Available from:
  35. Lip GYH, Blann AD, Jones AF, Lip PL, Beevers DG. Relation of endothelium, thrombogenesis, and hemorheology in systemic hypertension to ethnicity and left ventricular hypertrophy. Am J Cardiol 1997;80(12):1566–1571. DOI: 10.1016/s0002-9149(97)00749-2.
  36. Apicella M, Campopiano MC, Mantuano M, Mazoni L, Coppelli A, Del Prato S. COVID-19 in people with diabetes: understanding the reasons for worse outcomes. Lancet Diabetes Endocrinol 2020;8(9):782–792. DOI: 10.1016/S2213-8587(20)30238-2.
  37. Mishra Y, Pathak BK, Mohakuda SS, Tilak TVSVGK, Sen S, Harikrishnan P, et al. Relation of D-dimer levels of COVID-19 patients with diabetes mellitus. Diabetes Metab Syndr Clin Res Rev 2020;14(6):1927–1930. DOI: 10.1016/j.dsx.2020.09.035. Available from: /pmc/articles/PMC7528836/.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.